Advertisement

Drug Safety

, Volume 29, Issue 10, pp 926–926 | Cite as

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

  • J. Cobert
  • G. L. C. Ferreira
  • L. Wilton
  • S. A. W. Shakir
Abstracts

Keywords

Fluoxetine Paroxetine Sertraline Venlafaxine Fluvoxamine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 1998 Mar; 13(2): 63–73PubMedCrossRefGoogle Scholar
  2. 2.
    Hartmann PM. Mirtazapine: a newer antidepressant. Am Fam Physician 1999 Jan 1; 59(1): 159–61PubMedGoogle Scholar
  3. 3.
    Shakir SAW. Prescription-Event Monitoring. In: Strom B, editor. Pharmacoepidemiology. 4th ed. Chichester, UK: John Wiley & Sons Ltd, 2005: 203–16Google Scholar
  4. 4.
    Shakir SAW. Causality and Correlation in Pharmacovigilance. In: Waller P, Talbot J, editors. Stephens’ Detection of New Adverse Drug Reactions. 5th ed. Chichester, UK: John Wiley & Sons Ltd, 2004: 330–43Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • J. Cobert
    • 1
  • G. L. C. Ferreira
    • 1
    • 2
  • L. Wilton
    • 1
    • 2
  • S. A. W. Shakir
    • 1
    • 2
  1. 1.Drug Safety Research UnitSouthamptonUK
  2. 2.University of PortsmouthPortsmouthUK

Personalised recommendations